"I compliment you on development of this novel and innovative approach to AD…the idea of linking known facts about selective neuronal vulnerability with both novel biomarkers and novel therapeutics is really quite exciting and is something completely absent from current approaches focusing heavily on amyloid-beta and tau."
Chief Scientific Officer, Global Alzheimer’s Platform, Nov 2017
CEO and Founder
Baroness Greenfield is a British scientist, writer and broadcaster. Susan has published over 200 papers in peer-reviewed journals over the course of her distinguished career. She holds 32 honorary degrees from UK and foreign universities, and has received numerous honours including the Australian Medical Research Society Medal and Legion d’Honneur from the French Government. Susan also has an Honorary Fellowship from the Royal College of Physicians and is a member of the Fellowship of the Royal Society of Edinburgh.
David is an experienced manager and director having been Chairman and CEO of a number of companies across a wide variety of sectors.
He has a Master’s degree from Purdue University.
Dominique has experience sitting on a number of Boards, as a non-executive director, across the Healthcare sector. Her skills lie within business development and marketing.
Dominique has an MBA from Imperial University.